Ray McDermott
@RayMcDermott1
Medical Oncologist Patient Advocate Clinical Researcher Rugby Fan
Absolutely amazing!
Delighted to say that this year we raised a huge €240,000 which brings the total to €840,000 in 4 years. The Pat Smullen race day including the Curragh To Curragh cycle has now become the biggest fundraiser in Irish Racing. Thanks to everyone who donated to @cancertrials_ie
Succinct informative overview of PEACE III results by @RayMcDermott1. An advance in optimising treatment for mCRPC.Another great example of how Irish hospitals can be involved in advancing cancer care at a global level. @cancertrials_ie @CUH_Cork @CancerTrialCork @PaulKRadiation
🌟#ESMO24 Spotlight: The PEACE III (EORTC 1333) 📷 Prof. Ray McDermott (@RayMcDermott1 ) discusses the results of a phase III study investigating the combination of enzalutamide and alpharadin in men with metastatic castrate-resistant prostate cancer. 📷📷 The study found that…
We are very proud that the paper is online! Sincere thanks to our scientific committee and all panellists. Manuscript is open access, please use and distribute it! Hope to see you at the first edition of @APCCC_Lugano Diagnostics @ProfKHerrmann @stefanofanti4
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/articl… The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in…
A proud day. Thank you to everyone who donated and supported us. And especially to all my colleagues @PUNCHConsulting you guys are amazing 💙 @cancertrials_ie
Huge thanks to Jennifer Hayes @ucanstep & @PUNCHConsulting for a huge contribution to our charity cycle & the Pat Smullen raceday in aid of @cancertrials_ie held a month ago now. Brilliant stuff. What a lady. It’s 10 weeks since Jenn’s surgery & she’s flying it. 👏👏👏
@RayMcDermott1 's @cancertrials_ie 13-21 Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study - was a forerunner to PEACE 3 @EORTC 1333 trial pubmed.ncbi.nlm.nih.gov/34512801/
Great to see these positive results. Europe🇪🇺and collaborating 🇨🇦🇧🇷countries answering questions in prostate cancer. Nice to see Irish patient participation @CUH_Cork and Dublin🇮🇪 @cancertrials_ie @RayMcDermott1 #ESMO24 Congratukations to PIs @BertrandTOMBAL and @Silke_Gillessen
Outstanding talk from @Silke_Gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 @myESMO @OncoAlert @urotoday
It was clear to see the enormous impact of Pat Smullen's legacy at @curraghrace this Saturday. The funds raised by Pat's family, friends, and the horse racing community since 2019 have made new clinical trials and treatment options for patients with #PancreaticCancer possible.
We applaud the appointment of Prof Grainne O’Kane as the Pat Smullen Chair in Pancreatic Cancer @ucddublin The position is part-funded (€900K over 5 years) through the Pat Smullen Pancreatic Cancer Fund, with matching funding from @hseNCCP Read more: bit.ly/4fXyJta
Interesting podcast on why trials are necessary in Ireland. @RayMcDermott1 @cancertrials_ie @graokane @HSELive @SimonHarrisTD #KRAS #Braf #HER2 podcasts.apple.com/ie/podcast/lea…
In the coming weeks, we will start the first Irish study to trial a personalised cancer vaccine for patients with early-stage non-small cell lung cancer. It's a groundbreaking development and one of the first of such trials worldwide. Front page of today's Irish Examiner
Delighted to present the prognostic implications of PSA at 7mo in #mHSPC in this landmark analysis of #ENZAMET representing @cancertrials_ie and honoured to be a @ConquerCancerFd Merit award recipient @ChrisSweens1 @Prof_IanD @RayMcDermott1 @crashimminent @svuh @MaterCancer
Prognostic implications of PSA levels at 7 mo in #mHSPC treated with enzalutamide: landmark analysis of #ENZAMET (ANZUP 1304). Presented by @RonanAndrewMcL1 @pmcancercentre. #ASCO24 written coverage by @chavarriagaj @UofT > bit.ly/3yKx5KB @ASCO
We are so pleased for, and proud of our friend and colleague @SiobhanGaynor whose patient-led MBC study today informs not one but 2⃣ poster presentations @ASCO 2024. Sending oceans of goodwill across the pond to you from 🇮🇪!! @Seamusoreilly18 @EibhlinMulroe @AngelaClaytonL1
The FEED study, exploring the impact of a multimodal nutritional intervention in patients undergoing chemotherapy for #PancreaticCancer, is now open in @svuh. 👏 Congrats to PI's @RayMcDermott1, @OonaghGriffinRD and the team. Read more: bit.ly/4alHFEU #CancerResearch
🙌A huge thank you to @hannah_smullen, @TCDHorseRacing and everyone who came together to raise over €7800 at the Cheltenham Preview Night in aid of Cancer Trials Ireland! 📸@luke__oneill_, @hannah_smullen, @EibhlinMulroe & Emma Osborne. @francescrowley #CancerResearch…
Second BCR (without correlate on NGI) after salvage radiation and/or after metastases directed therapy: How to manage these patients? Presented by @RayMcDermott1 @svuh. #APCCC24 Written coverage by @zklaassen_md @GACancerCenter on UroToday > bit.ly/3QkiRWJ @APCCC_Lugano
Key points from @RayMcDermott1 on PSA recurrence. Note the first one - I’ve lost count of the number of times the solution to the unexpected progression (including known M1) was “the other doc told me I could stop the injections and I haven’t had one for 2 years.” #APCCC24
Survey based research conducted by our team in Tallaght University Hospital, describing the negative impact of testicular cancer on survivors. Unfortunately, not enough support systems are in place at present to cater their needs. #ServeTheSurvivors #CancerSurvivors
📅 April marks Testicular Cancer Awareness Month. 📋 A team from @TUH_Tallaght recently evaluated how testicular cancer impacts the socioeconomic and sexual health of young survivors. ➡️ Learn more: buff.ly/48Zfwmj #TesticularCancerAwarenessMonth
Many thanks to @myESMO for providing wonderful opportunity and platform to highlight our work. Had insightful conversations with oncologists around the world. We hope our work will improve survivorship care for all cancer patients #EsmoSarcomaandRareTumour24 #CancerSurvivor